RECURSION PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01 Other Events.


Press Release

On October 7, 2021, Recursion Pharmaceuticals, Inc. issued a press release announcing the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for REC-2282 for the potential treatment of NF-2 mutated meningiomas. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



Exhibit No.       Description

99.1                Press Release, dated October 7, 2021.

104               Cover Page Interactive Data File (embedded within the Inline XBRL
                  document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses